ARCHIVES

Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.

This article is from The Cancer Letter archive.

Vol. 31 No. 35 | September 30, 2005

Download PDF Visit The Full Archive

Related Articles

Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials

March 25, 2011

FDA Codifies Rules For Expanded Access, Charging For Drugs In Clinical Trials.

December 22, 2006

Blackburn Wins BMS Award

May 23, 2003

In Brief: Jane Henney, Former NCI Deputy Director, Named FDA Deputy Commissioner For Operations

November 15, 1991

HPV Vaccine Cervarix Active In 100% Of Women In Study

July 27, 2007

HRSA: Discounts Owed on Some Orphan Drug Uses

October 24, 2014